Your browser doesn't support javascript.
loading
PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.
Meehan, Terrence F; Conte, Nathalie; Goldstein, Theodore; Inghirami, Giorgio; Murakami, Mark A; Brabetz, Sebastian; Gu, Zhiping; Wiser, Jeffrey A; Dunn, Patrick; Begley, Dale A; Krupke, Debra M; Bertotti, Andrea; Bruna, Alejandra; Brush, Matthew H; Byrne, Annette T; Caldas, Carlos; Christie, Amanda L; Clark, Dominic A; Dowst, Heidi; Dry, Jonathan R; Doroshow, James H; Duchamp, Olivier; Evrard, Yvonne A; Ferretti, Stephane; Frese, Kristopher K; Goodwin, Neal C; Greenawalt, Danielle; Haendel, Melissa A; Hermans, Els; Houghton, Peter J; Jonkers, Jos; Kemper, Kristel; Khor, Tin O; Lewis, Michael T; Lloyd, K C Kent; Mason, Jeremy; Medico, Enzo; Neuhauser, Steven B; Olson, James M; Peeper, Daniel S; Rueda, Oscar M; Seong, Je Kyung; Trusolino, Livio; Vinolo, Emilie; Wechsler-Reya, Robert J; Weinstock, David M; Welm, Alana; Weroha, S John; Amant, Frédéric; Pfister, Stefan M.
Afiliação
  • Meehan TF; European Molecular Biology Laboratory-European Bioinformatics Institute, Hinxton, United Kingdom. tmeehan@ebi.ac.uk.
  • Conte N; European Molecular Biology Laboratory-European Bioinformatics Institute, Hinxton, United Kingdom.
  • Goldstein T; Institute for Computational Health Sciences, University of California, San Francisco, California.
  • Inghirami G; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
  • Murakami MA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Brabetz S; Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.
  • Gu Z; Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Wiser JA; Northrop Grumman Information Systems Health IT, Rockville, Maryland.
  • Dunn P; Northrop Grumman Information Systems Health IT, Rockville, Maryland.
  • Begley DA; Northrop Grumman Information Systems Health IT, Rockville, Maryland.
  • Krupke DM; The Jackson Laboratory, Bar Harbor, Maine.
  • Bertotti A; The Jackson Laboratory, Bar Harbor, Maine.
  • Bruna A; Candiolo Cancer Institute, FPO-IRCC, Department of Oncology, University of Torino, Torino, Italy.
  • Brush MH; Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge, United Kingdom.
  • Byrne AT; Department of Medical Informatics and Clinical Epidemiology and OHSU Library, Oregon Health and Science University, Portland, Oregon.
  • Caldas C; Royal College of Surgeons in Ireland, Ireland.
  • Christie AL; Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge, United Kingdom.
  • Clark DA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Dowst H; European Molecular Biology Laboratory-European Bioinformatics Institute, Hinxton, United Kingdom.
  • Dry JR; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.
  • Doroshow JH; Oncology Innovative Medicines and Early Development, AstraZeneca R&D Boston, Waltham, Massachusetts.
  • Duchamp O; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Evrard YA; Oncodesign Biotechnology and IMODI Consortium, France.
  • Ferretti S; Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Frese KK; Oncology Disease Area, Novartis Institutes for Biomedical Research, Switzerland.
  • Goodwin NC; Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Greenawalt D; Champions Oncology, Baltimore, Maryland.
  • Haendel MA; Translational Bioinformatics Bristol-Myers Squibb, Pennington, New Jersey.
  • Hermans E; Department of Medical Informatics and Clinical Epidemiology and OHSU Library, Oregon Health and Science University, Portland, Oregon.
  • Houghton PJ; Katholieke Universiteit Leuven, Leuven, Belgium.
  • Jonkers J; Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
  • Kemper K; The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Khor TO; The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Lewis MT; Institute for Applied Cancer Science, Center for Co-Clinical Trial, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lloyd KCK; The Lester and Sue Smith Breast Center, Departments of Molecular and Cellular Biology and Radiology, Baylor College of Medicine, Houston, Texas.
  • Mason J; Department of Surgery, School of Medicine, and Mouse Biology Program, University of California Davis, Davis, California.
  • Medico E; European Molecular Biology Laboratory-European Bioinformatics Institute, Hinxton, United Kingdom.
  • Neuhauser SB; Candiolo Cancer Institute, FPO-IRCC, Department of Oncology, University of Torino, Torino, Italy.
  • Olson JM; The Jackson Laboratory, Bar Harbor, Maine.
  • Peeper DS; Fred Hutchinson Cancer Research Center, Seattle Children's Hospital, Seattle, Washington.
  • Rueda OM; The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Seong JK; Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge, United Kingdom.
  • Trusolino L; Research Institute for Veterinary Science and Korea Mouse Phenotyping Center, Seoul, Republic of Korea.
  • Vinolo E; Candiolo Cancer Institute, FPO-IRCC, Department of Oncology, University of Torino, Torino, Italy.
  • Wechsler-Reya RJ; Seeding Science SAS, Paris, France.
  • Weinstock DM; Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, La Jolla, California.
  • Welm A; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Weroha SJ; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Amant F; Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota.
  • Pfister SM; The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Cancer Res ; 77(21): e62-e66, 2017 11 01.
Article em En | MEDLINE | ID: mdl-29092942
ABSTRACT
Patient-derived tumor xenograft (PDX) mouse models have emerged as an important oncology research platform to study tumor evolution, mechanisms of drug response and resistance, and tailoring chemotherapeutic approaches for individual patients. The lack of robust standards for reporting on PDX models has hampered the ability of researchers to find relevant PDX models and associated data. Here we present the PDX models minimal information standard (PDX-MI) for reporting on the generation, quality assurance, and use of PDX models. PDX-MI defines the minimal information for describing the clinical attributes of a patient's tumor, the processes of implantation and passaging of tumors in a host mouse strain, quality assurance methods, and the use of PDX models in cancer research. Adherence to PDX-MI standards will facilitate accurate search results for oncology models and their associated data across distributed repository databases and promote reproducibility in research studies using these models. Cancer Res; 77(21); e62-66. ©2017 AACR.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Antitumorais Modelo de Xenoenxerto / Neoplasias Tipo de estudo: Guideline Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Antitumorais Modelo de Xenoenxerto / Neoplasias Tipo de estudo: Guideline Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article